ABL1在肝细胞癌中过表达并调控NOTCH1促进小鼠肝脏肿瘤发展
研究分析TCGA数据及小鼠模型发现,肝细胞癌组织ABL1水平高于非肿瘤肝组织且与患者较短生存时间相关。肝细胞特异性敲除Abl1使小鼠肝脏肿瘤缩小50%、中位生存期从64天延长至81天,ABL1抑制剂尼罗替尼可减缓小鼠肝脏肿瘤生长并降低MYC和NOTCH1水平。
要点
- 肝细胞癌组织ABL1水平高于非肿瘤肝组织,且与患者较短生存时间相关。
- 肝细胞特异性敲除Abl1使小鼠肝脏肿瘤缩小50%,中位生存期从64天延长至81天。
- ABL1抑制剂尼罗替尼可减缓小鼠肝脏肿瘤生长并降低MYC和NOTCH1水平。
核心结论
- 肝细胞癌样本ABL1水平高于非肿瘤肝组织,且ABL1水平升高与患者较短生存时间相关。
- 缺失或抑制ABL1可减少肝细胞癌细胞增殖并减缓小鼠肝脏肿瘤生长。
- ABL1抑制剂可能用于肝细胞癌治疗。
研究设计与样本
- 分析TCGA临床与基因表达数据。
- 使用Albumin-Cre(HepWT)小鼠和肝细胞特异性敲除Abl1(HepAbl-/-)小鼠,经流体动力学注射编码Sleeping Beauty转座酶及含MET基因和N端截短catenin β1基因的转座子质粒诱导肝脏肿瘤。
- 部分小鼠每日灌胃ABL1抑制剂尼罗替尼或对照溶剂共4周。
- 在Hep3B和Huh7肝细胞癌细胞中用shRNA敲低ABL1,分析增殖及小鼠异种移植瘤生长。
- 对肿瘤进行RNA测序和基因集富集分析;在肝细胞癌细胞中敲低或过表达NOTCH1和MYC并分析增殖;用肝细胞癌组织芯片免疫组化检测磷酸化ABL1、MYC和NOTCH1水平。
主要发现
- 肝细胞癌组织ABL1水平高于非肿瘤肝组织,且与患者较短生存时间相关。
- HepWT小鼠经MET和catenin β1转座子诱导后发生肝脏肿瘤,中位生存64天;HepAbl-/-小鼠肿瘤缩小50%,中位生存81天。
- 在人肝细胞癌细胞中敲低ABL1可减少增殖、小鼠异种移植瘤生长及MYC表达,进而降低NOTCH1表达。
- 在肝细胞癌细胞中敲低NOTCH1或MYC显著减少细胞生长;过表达NOTCH1或MYC促进增殖并挽救ABL1敲低所致表型。
- 人肝细胞癌标本中磷酸化(活化)ABL1水平与MYC和NOTCH1水平相关。
临床怎么用
- 肝细胞癌组织ABL1水平升高且与较短生存相关,提示ABL1可能作为预后相关标志物。
- ABL1抑制剂尼罗替尼在临床前模型中减缓肝脏肿瘤生长,提示ABL1抑制剂可能用于肝细胞癌治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: We investigated whether ABL proto-oncogene 1, non-receptor tyrosine kinase (ABL1) is involved in development of hepatocellular carcinoma (HCC). METHODS: We analyzed clinical and gene expression data from The Cancer Genome Atlas. Albumin-Cre (HepWT) mice and mice with hepatocyte-specific disruption of Abl1 (HepAbl-/- mice) were given hydrodynamic injections of plasmids encoding the Sleeping Beauty transposase and transposons with the MET gene and a catenin β1 gene with an N-terminal truncation, which induces development of liver tumors. Some mice were then gavaged with the ABL1 inhibitor nilotinib or vehicle (control) daily for 4 weeks. We knocked down ABL1 with short hairpin RNAs in Hep3B and Huh7 HCC cells and analyzed their proliferation and growth as xenograft tumors in mice. We performed RNA sequencing and gene set enrichment analysis of tumors. We knocked down or overexpressed NOTCH1 and MYC in HCC cells and analyzed proliferation. We measured levels of phosphorylated ABL1, MYC, and NOTCH1 by immunohistochemical analysis of an HCC tissue microarray. RESULTS: HCC tissues had higher levels of ABL1 than non-tumor liver tissues, which correlated with shorter survival times of patients. HepWT mice with the MET and catenin β1 transposons developed liver tumors and survived a median 64 days; HepAbl-/- mice with these transposons developed tumors that were 50% smaller and survived a median 81 days. Knockdown of ABL1 in human HCC cells reduced proliferation, growth as xenograft tumors in mice, and expression of MYC, which reduced expression of NOTCH1. Knockdown of NOTCH1 or MYC in HCC cells significantly reduced cell growth. NOTCH1 or MYC overexpression in human HCC cells promoted proliferation and rescued the phenotype caused by ABL1 knockdown. The level of phosphorylated (activated) ABL1 correlated with levels of MYC and NOTCH1 in human HCC specimens. Nilotinib decreased expression of MYC and NOTCH1 in HCC cell lines, reduced the growth of xenograft tumors in mice, and slowed growth of liver tumors in mice with MET and catenin β1 transposons, reducing tumor levels of MYC and NOTCH1. CONCLUSIONS: HCC samples have increased levels of ABL1 compared with nontumor liver tissues, and increased levels of ABL1 correlate with shorter survival times of patients. Loss or inhibition of ABL1 reduces proliferation of HCC cells and slows growth of liver tumors in mice. Inhibitors of ABL1 might be used for treatment of HCC.
引用
- Wang F, Hou W, Chitsike L, et al. ABL1, Overexpressed in Hepatocellular Carcinomas, Regulates Expression of NOTCH1 and Promotes Development of Liver Tumors in Mice. Gastroenterology. 2020. PMID: 32171747. doi:10.1053/j.gastro.2020.03.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。